Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New obesity drug combo shows promise in early trial

NCT ID NCT04969939

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested whether adding an experimental drug (NNC0165-1875) to the weight-loss medication semaglutide helps people with obesity lose more weight. 120 adults with a BMI between 30 and 45 took part. Participants received either the drug combo or semaglutide plus a placebo, with two injections per week. The study lasted about 26 weeks and looked at safety and weight change.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NNC0165-1875 (an experimental drug) added to semaglutide
What this could lead to
If it works, this could lead to a more effective weight-loss treatment for people with obesity.
What could go wrong
This is a small, early-phase trial (phase 2) with only 120 participants. The drug combination may not prove safe or effective in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

120 people

The number who actually took part.

Started

Jul 2021

Finished

Jan 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial. * Male or female, age above or equal to 18 years at the time of signing informed consent. * BMI 30.0-45.0 kg/m\^2 (both inclusive) at the screening visit. Exclusion Criteria: * HbA1c greater than or equal to 48 mmol/mol (6.5%) as measured by a central laboratory at screening. * History of type 1 or type 2 diabetes mellitus. * Treatment with glucose-lowering agent(s) within 90 days before screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

Contacts and locations

Locations

  • AMC Community Endocrinology

    Albany, New York, 12206, United States

  • Accellacare

    Wilmington, North Carolina, 28401, United States

  • Altasciences Clinical Kansas, Inc.

    Overland Park, Kansas, 66212, United States

  • Anaheim Clinical Trials, LLC

    Anaheim, California, 92801, United States

  • Chrysalis Clinical Research

    St. George, Utah, 84790, United States

  • Coastal Carolina Res Ctr.

    North Charleston, South Carolina, 29405, United States

  • Diablo Clinical Research, Inc.

    Walnut Creek, California, 94598, United States

  • East West Med Res Inst

    Honolulu, Hawaii, 96814, United States

  • Endo Res Solutions Inc

    Roswell, Georgia, 30076, United States

  • Evanston Premier Hlthcr Res

    Skokie, Illinois, 60077, United States

  • Health Res of Hampton Roads

    Newport News, Virginia, 23606, United States

  • Jacksonville Ctr For Clin Res

    Jacksonville, Florida, 32216, United States

  • L-MARC Research Center

    Louisville, Kentucky, 40213, United States

  • Medical Uni of SC Charleston

    Charleston, South Carolina, 29425, United States

  • NYC Research, Inc.

    New York, New York, 10016, United States

  • National Clin Res Inc.

    Richmond, Virginia, 23294, United States

  • PharmQuest Life Sciences LLC

    Greensboro, North Carolina, 27408, United States

  • Profil Institute For Clinical Research Inc

    Chula Vista, California, 91911, United States

  • Selma Medical Associates

    Winchester, Virginia, 22601-3834, United States

  • Soltero Cardiovascular Research Center

    Dallas, Texas, 75226, United States

  • Texas Diabetes & Endocrinology, P.A._Austin

    Austin, Texas, 78749, United States

  • Texas Diabetes & Endocrinology, P.A._Austin

    Round Rock, Texas, 78681, United States

  • Univ of Alabama Birmingham

    Birmingham, Alabama, 35294, United States

  • Velocity Clin Res Los Angeles

    Los Angeles, California, 90017, United States

  • Washington Cntr Weight Mgmt

    Arlington, Virginia, 22206, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.